Potential natural immunization against atherosclerosis in hibernating bears.

Scientific Reports
Shailesh Kumar SamalJohan Frostegård

Abstract

Brown bears (Ursus arctos) hibernate for 5-6 months during winter, but despite kidney insufficiency, dyslipidemia and inactivity they do not seem to develop atherosclerosis or cardiovascular disease (CVD). IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) are associated with less atherosclerosis, CVD and mortality in uremia in humans and have anti-inflammatory and other potentially protective properties. PC but not MDA is exposed on different types of microorganisms. We determine anti-PC and anti-MDA in brown bears in summer and winter. Paired serum samples from 12 free ranging Swedish brown bears were collected during hibernation in winter and during active state in summer and analyzed for IgM, IgG, IgG1/2 and IgA anti-PC and anti-MDA by enzyme linked immunosorbent assay (ELISA). When determined as arbitrary units (median set at 100 for summer samples), significantly raised levels were observed in winter for anti-PC subclasses and isotypes, and for IgA anti-PC the difference was striking; 100 IQR (85.9-107.9) vs 782.3, IQR (422.8-1586.0; p < 0.001). In contrast, subclasses and isotypes of anti-MDA were significantly lower in winter except IgA anti-MDA, which was not detectable. Anti-PCs are sign...Continue Reading

References

May 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·J FrostegårdL Schäfer-Elinder
Sep 9, 1999·Journal of Wildlife Diseases·R J GauB T Elkin
Aug 7, 2007·Journal of the American College of Cardiology·Giuseppina CaligiuriAntonino Nicoletti
May 6, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yifang ChenGregg J Silverman
Jun 25, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Juan Jesús CarreroJohan Frostegård
Sep 18, 2009·Annals of the New York Academy of Sciences·Nancy Agmon-LevinYehuda Shoenfeld
Jan 5, 2012·Endocrine, Metabolic & Immune Disorders Drug Targets·Lamyaa Al-Riyami, William Harnett
Feb 7, 2012·International Journal of Cardiology·Kenneth CaidahlJohan Frostegård
Dec 21, 2012·Kidney International·Peter StenvinkelRichard J Johnson
May 3, 2013·BMC Medicine·Johan Frostegård
Apr 15, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Roland FiskesundJohan Frostegård
Aug 12, 2014·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Christian A GleissnerGrigorios Korosoglou
Feb 11, 2015·International Journal for Parasitology·Tamar R AprahamianIan R Rifkin
May 6, 2015·European Journal of Clinical Investigation·Benjamin WildeJan Willem Cohen Tervaert
Sep 10, 2016·The Journal of Biological Chemistry·Karen Gjesing WelinderOle Frøbert
Dec 22, 2016·Journal of the American Heart Association·Divya ThiagarajanJohan Frostegård
May 10, 2017·Parasitology Research·S V BugmyrinA S Kuznetsova
Oct 9, 2019·Journal of Internal Medicine·O FröbertM T Overgaard
Dec 11, 2019·Antibodies·Patrícia de Sousa-Pereira, Jenny M Woof
Dec 12, 2019·Journal of Internal Medicine·L DaiP Stenvinkel
Jan 16, 2020·Scientific Reports·Peter Godsk JørgensenOle Fröbert
Apr 17, 2020·Clinical and Experimental Immunology·Shailesh Kumar SamalJohan Frostegård
Sep 6, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Divya ThiagarajanJohan Frostegård

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

GraphPad Prism
GraphPad

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.